While no specific FDA-approved therapies for TFE3-rearranged RCC are formulated, its molecular features suggest potential benefits from MET or VEGF pathway inhibitors, while immunotherapy with immune checkpoint inhibitors is also an alternative. This evidence concerns the gene VEGFA and renal cell carcinoma.